Our academic collaborators’ seminal contributions push the field forward
Our constellation of renowned thinkers and partners
The right collaborators across pharma, biotech and nonprofit
The next generation of scientific leaders in cancer immunotherapy
Stories & Announcements
PICI in the News
Resources for Press
An Immunologist Breaks Down COVID-19
2019 Annual Report
The Parker Institute for Cancer Immunotherapy Awards $2.75 Million to Support Six Early Career Researchers from Leading Research Institutions
Develop breakthrough immune therapies to turn all cancers into curable diseases faster
The driving force behind PICI’s research and operations
Transformative science requires visionary philanthropy
Join us. Change lives.
Multi-center clinical trials take years to launch, slowing progress. At PICI, we design groundbreaking immunotherapy studies that move forward at the speed of life. Together with leading academic, industry and nonprofit partners, we answer the hard questions in the toughest-to-treat cancers. Always asking why some therapies work while others don’t. Our secret weapon: in-house trials management and translational medicine experts who speed trials from concept to finish line, so that discoveries can benefit cancer patients faster.
Trials in progress
Ramy Ibrahim, MD
Chief Medical Officer
Theresa LaVallee, PhD
Vice President of Clinical Development and Regulatory Affairs
Justin Fairchild, MPH
Executive Director, Clinical Development
Holly Huntington, RN, BSN
Director, Clinical Trial Operations
How We’re Different
A Study of Novel Combination Therapies for Metastatic Prostate Cancer
A Study to Explore Patient Response to Checkpoint Inhibitors in Advanced Melanoma
Pancreatic Cancer: Can a Combination of Immunotherapy and Chemotherapy Defeat It?
Cancer-Fighting T-Cells Engineered Using CRISPR
The Microbiome and Cancer: Can Gut Bacteria Help Immunotherapy Destroy Tumors?
Taking Cancer’s Temperature: Biomarkers for Checkpoint Response in Hot vs. Cold Tumors